Recursion will host its second quarter financial results and business updates in an Earnings Call on August 5, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST.
Join the call on:
▪️LinkedIn: linkedin.com/company/recurs…
▪️YouTube: youtube.com/@RecursionPhar…
▪️X: x.com/RecursionPharma
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.
- We’re improving clinical trials with AI before the first patient enrolls. A new article from Brian Buntz in @RandDWorld highlights the current roadblocks in clinical trials and how Recursion is improving the process with a data- and AI-driven approach. Today, protocols are on
- @hoifungpoon, PhD, formerly General Manager of @MSFTResearch, has joined Recursion as the company’s first Chief AI Officer. He spent more than 15 years at Microsoft and led pioneering work in biomedical AI, multimodal foundation models, and causal machine learning. His
- 📣 Presenting a new method for recognizing which tumors are most likely to benefit from dsRNA therapies. At @AACR Drug Discovery and Development (AACR D3), July 21-24 in Boston, Recursion will present the poster “Identifying actionable dsRNA biomarkers from sense-antisense
- 🚀 A better, faster co-folding-based binding affinity model. Predicting how tightly a drug candidate binds to its target is critical in drug discovery. It also requires massive computational resources. State-of-the-art models can take 20 seconds to a minute per prediction,

